← Back to Home

Six-Year Follow-Up in Adjuvant Breast Cancer Treatment: Higher Survival in the Kisqali Group, but Statistical Interpretation Still Requires Caution

The phase III NATALEE trial shows a 2.2-percentage-point increase in six-year overall survival with the addition of ribociclib. This provides new long-term evidence for postoperative treatment, but the descriptive analysis and smaller subgroup samples also define the limits of what the results can answer.

By SURL BioNews

For patients with early breast cancer, the long-term goals of postoperative treatment are to reduce recurrence and help more people live longer. The latest six-year follow-up from the phase III NATALEE trial offers a positive signal for the latter: patients with hormone receptor-positive, HER2-negative disease had better overall survival with ribociclib (brand name Kisqali) added to endocrine therapy than with endocrine therapy alone. However, the statistical nature of this analysis still requires careful interpretation.

According to CancerNetwork, the study compared ribociclib plus a nonsteroidal aromatase inhibitor with this type of endocrine drug alone in patients with stage II or III early breast cancer. Data compiled by OncoDaily show that the data cutoff was May 15, 2026, with a median follow-up for overall survival of 66.5 months. The “six-year results” refer to survival estimates at the six-year time point, rather than all patients having completed six years of follow-up.

Six-year overall survival was 91.9% in the combination therapy group and 89.7% in the control group, a difference of 2.2 percentage points. The hazard ratio for death was 0.809, representing an approximately 19% reduction in the relative risk of death during follow-up. This relative reduction and the absolute difference in six-year survival rates are two distinct ways of understanding efficacy and should not be conflated.

The figures still have statistical limitations. The 95% confidence interval for the hazard ratio for death was 0.661 to 0.989, and the nominal one-sided P value was 0.019. However, CancerNetwork noted that this overall survival analysis was descriptive and that the testing was also nominal. Thus, although the results favored combination therapy, the P value alone should not be taken as establishing a confirmatory survival conclusion.

Disease control results provide another layer of support. OncoDaily reported that six-year invasive disease-free survival was 83.23% in the combination therapy group and 77.92% in the control group, a difference of approximately 5.3 percentage points; the hazard ratio was 0.741, with a 95% confidence interval of 0.646 to 0.849. This endpoint measures invasive disease-related events or death and differs from overall survival, which considers only death. Together, the two describe the long-term effects of treatment.

A Bloomberg report published through SWI swissinfo.ch quoted Fumikata Hara, an independent commentator at the European Society for Medical Oncology annual congress, as saying that the survival results were clinically meaningful, while cautioning that treatments received after recurrence could also affect overall survival. He also noted that some lower-risk subgroups had fewer patients and events, making the evidence less certain. The same magnitude of benefit therefore cannot simply be assumed for every patient group.

This follow-up extends the evidence for adjuvant ribociclib from disease control to a longer-term survival signal. Determining which patients benefit most still requires interpretation alongside each subgroup’s baseline recurrence risk, treatment burden, and safety data. The reporting summaries currently provided are also insufficient to fully assess these trade-offs.

References

  1. CancerNetwork
  2. Bloomberg via SWI swissinfo.ch
  3. OncoDaily